[Featured Stock] Samsung Pharmaceutical Hits Upper Limit on Securing Domestic Rights for Alzheimer’s Treatment
Samsung Pharmaceutical soared to the upper limit price immediately after the market opened.
At 9:19 AM on the 26th, Samsung Pharmaceutical was trading at 3,675 KRW, up 29.86% compared to the previous trading day.
On the previous day, GemVax & Kael (GemVax) announced that it had signed a technology transfer agreement with Samsung Pharmaceutical regarding the domestic clinical development and commercialization rights of the Alzheimer's disease treatment GV1001. As a result, Samsung Pharmaceutical now holds GV1001, which has demonstrated potential as an Alzheimer's disease treatment, as a key clinical pipeline, gaining the rights to conduct Phase 3 clinical trials domestically and to commercialize the drug within Korea.
Hot Picks Today
"Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- "Not Jealous of Winning the Lottery"... Entire Village Stunned as 200 Million Won Jackpot of Wild Ginseng Cluster Discovered at Jirisan
- Bull Market End Signal? Securities Firm Warns: "Sell SK hynix 'At This Moment'"
- "Looks Even More Like Him in Person": Crowds Gather to See 'Trump Lookalike' Albino Buffalo
- "Even With a 90 Million Won Salary and Bonuses, It Doesn’t Feel Like Much"... A Latecomer Rookie Who Beat 70 to 1 Odds [Scientists Are Disappearing] ③
GV1001 is undergoing clinical trials simultaneously in Korea and globally (the United States and seven European countries). Through a Phase 2 clinical trial conducted in Korea on patients with moderate to severe Alzheimer's disease, its efficacy and safety were demonstrated. Currently, the Phase 3 clinical trial plan (IND) has been approved, and preparations for the clinical trial are underway.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
